Amgen Plans $25-Million Offering

Seeking to capitalize on a strong stock market and renewed interest in biotechnology stocks, Amgen, a Newbury Park biotechnology company, is planning a public stock offering to raise roughly $25 million, the company said.

Amgen filed a registration statement Feb. 3 with the Securities and Exchange Commission for 2 million new shares. It already has about 11 million shares outstanding, traded over the counter. A company spokesman said that, contingent on SEC approval, the offering will be in mid-March, with proceeds to be used for research, clinical tests, expanded manufacturing facilities and additional working capital.

Kidder, Peabody and Montgomery Securities are the underwriters.